X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-6-2022-1657105109.pdf
https://www.fiercepharma.com/pharma/watch-out-pfizer-alnylam-astrazeneca-wades-deeper-into-rare-disease-ionis-tie-up
https://www.prnewswire.com/news-releases/tegsedi-receives-innovative-drug-category-pricing-in-brazil-301396505.html
https://www.prnewswire.com/news-releases/ionis-and-akcea-win-prestigious-prix-galien-award-for-tegsedi-inotersen-as-best-biotechnology-product-301163758.html
https://www.prnewswire.com/news-releases/akcea-announces-approval-for-reimbursement-of-tegsedi-inotersen-in-austria-for-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy-301096646.html
https://www.prnewswire.com/news-releases/akcea-announces-approval-for-reimbursement-of-tegsedi-inotersen-in-italy-for-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy-301070225.html
https://www.prnewswire.com/news-releases/akcea-announces-approval-for-reimbursement-of-tegsedi-inotersen-in-portugal-for-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy-301068060.html
https://www.pharmiweb.com/press-release/2020-05-28/akcea-and-ionis-announce-publication-of-long-term-clinical-data-of-tegsedi-in-patients-with-polyneuropathy-driven-by-hereditary-transthyretin-amyloid
https://www.newswire.ca/news-releases/akcea-therapeutics-canada-confirms-letter-of-intent-with-pan-canadian-pharmaceutical-alliance-for-tegsedi-tm-inotersen-injection--855519610.html
https://www.fiercepharma.com/marketing/akcea-taps-first-chief-commercial-officer-as-waylivra-debuts-and-pipeline-advances
https://www.contractpharma.com/contents/view_breaking-news/2019-10-24/akcea-therapeutics-appoints-chief-commercial-officer/
https://www.fiercebiotech.com/biotech/ionis-cbo-takes-over-akcea-as-ceo-cbo-and-coo-head-out-door
http://www.pharmatimes.com/news/smc_rejects_orkambi,_accepts_four_medicines_1297290
https://www.fiercepharma.com/marketing/alnylam-s-onpattro-back-game-ionis-thanks-to-nice-u-turn?utm_source=internal&utm_medium=rss
http://www.pharmatimes.com/news/final_nice_guidance_issued_for_akceas_tegsedi_1289083
http://www.pharmafile.com/news/522420/akceas-tegsedi-secures-nice-approval-stage-1-or-2-polyneuropathy-hattr
http://www.pharmafile.com/news/521349/nice-recommends-akceas-tegsedi-rare-life-threatening-progressive-disease
http://www.pmlive.com/pharma_news/akcea_steals_march_on_alnylam_with_nice_approval_1284584
https://www.fiercepharma.com/pharma/ionis-tegsedi-gets-a-boost-u-k-after-nice-reverses-initial-guidance
http://www.pharmafile.com/news/519638/nice-reject-two-treatments-fatal-ultra-rare-disease-hattr
https://endpts.com/ionis-and-akcea-get-their-shot-at-competing-with-alnylam-for-a-rare-disease-group-but-its-not-expected-to-be-pretty/
https://www.reuters.com/article/us-akcea-fda/akcea-therapeutics-genetic-disease-treatment-gets-fda-approval-idUSKCN1MF2OP
https://www.xconomy.com/san-diego/2018/08/27/fda-gives-thumbs-down-to-rare-disease-drug-from-ionis-akcea/
https://www.fiercebiotech.com/biotech/fda-nixes-akcea-s-volanesorsen-despite-favorable-adcomm
https://www.bizjournals.com/boston/news/2018/08/27/fda-rejects-rare-liver-disease-drug-developed-by.html
https://www.reuters.com/article/us-akcea-fda/fda-declines-to-approve-akcea-ionis-genetic-disease-drug-idUSKCN1LC28W
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004782/WC500253279.pdf
https://www.prnewswire.com/news-releases/ionis-htt-rx-rg6042-granted-prime-designation-by-the-european-medicines-agency-for-the-treatment-of-people-with-huntingtons-disease-300691421.html
https://www.prnewswire.com/news-releases/akcea-therapeutics-and-ptc-therapeutics-collaborate-to-commercialize-two-rare-disease-drugs-in-latin-america-300690950.html
https://www.prnewswire.com/news-releases/ionis-closes-strategic-collaboration-with-biogen-to-develop-drugs-for-a-broad-range-of-neurological-diseases-300660168.html
https://www.fiercebiotech.com/biotech/fda-delays-decision-inotersen-handing-lead-to-alnylam
https://endpts.com/swapping-stock-and-cash-ionis-turns-to-closely-controlled-akcea-for-a-deal-on-spurned-drug-inotersen/
Market Place
Share 
